SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending following a notable price breakout past resistance, sparking intense debate as bulls celebrate liquidated shorts and bears anticipate a bull trap. Community discussion is focused on BTC's potential as a safe haven amid geopolitical tensions, alongside former President Trump's strong advocacy for crypto-friendly legislation.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is gaining significant traction following a definitive commercial agreement and strategic investment from TELUS, reinforcing its commercial validation and financial runway. The community is overwhelmingly bullish on the company's strong earnings, projecting substantial revenue growth and accelerating satellite deployment, particularly as it displays remarkable strength amidst a challenging market.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as reports indicate major automakers are exiting its EU carbon credit pool, potentially impacting a revenue stream, while Elon Musk's ambitious push into AI and humanoid robotics sparks intense community debate over the company's future direction amidst broader market volatility.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is gaining significant momentum as the community eagerly anticipates Phase 3 results for its promising AML drug, GPS, with many anticipating a potential buyout fueled by conviction in the science and high short interest, leading to strong expectations of a major upward repricing. Investors are actively discussing the drug's "functional cure" potential and celebrating the stock's multi-year highs.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is trending as a highly leveraged play on Bitcoin's rebound, fueled by significant institutional inflows into crypto and the company's continuous BTC acquisitions. Community sentiment is sharply polarized between bulls anticipating a short squeeze and bears concerned about share dilution amidst volatile market conditions.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd (INDO) is trending as it experiences a significant pullback despite surging crude oil prices and escalating Middle East tensions, which is causing community members to debate if it's due to market manipulation, dilution, or a 'shakeout' before a larger move similar to its 2022 rally. This comes as other low-float energy stocks are seeing substantial gains, fueling speculation about INDO's unique price action amidst the geopolitical "war trade" narrative.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

Marathon Digital Holdings is trending due to its strategic pivot into AI/HPC data centers via a partnership with Starwood Capital Group and an updated policy allowing opportunistic Bitcoin sales, shifting its identity beyond a pure crypto miner. The community is actively debating the potential for a sustained rally and short squeeze driven by this diversification, even amidst ongoing critiques of management and the company's Bitcoin price correlation.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle is trending sharply upward after its robust Q4 earnings reported significant growth in USDC circulation and profitability, fueling a massive short squeeze. The community is buzzing about its foundational role in AI agentic commerce and its potential to benefit from both favorable stablecoin regulation and persistent interest rate levels.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

Kendu Crypto is trending as its dedicated community champions extensive real-world brand building through initiatives like KENDU SPICE and energy drinks, coupled with its verified token presence across Ethereum and Base. Members are actively engaged in dollar-cost averaging and showcasing strong conviction in the project's long-term vision, distinguishing it as a brand-focused entity in the crypto space.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending amid high anticipation for its upcoming earnings, as the community fiercely debates its valuation and strategic position in the evolving Agentic AI landscape. Investors are polarized between those highlighting its strong balance sheet, institutional ownership, and role as an AI orchestration platform, and those concerned about competition and recent price weakness, fueling speculation of a potential short squeeze.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$SLS Just a reminder that there are 99.99% chances of success for REGAL.  Failure is a statistical impossibility. 
 
For context, before the mixed-cure model, I built several different models.  I&#39;ve attached the convergence and divergence between 6 models, that all lead to the same/similar result during the trial duration.  
 
Pure Cure: S(t) = p + (1-p)·exp(-λt) 67.9% cured forever  
Leaky Cure: &quot;cured&quot; patients relapse at 1-10% per year  
Weibull: S(t) = exp(-(t/η)^β) decelerating hazard, no plateau  
Log-Normal: heavy right tail, no true cure  
Piecewise Exponential: fast early decline, slow late decline  
 
The straight HR when BAT = 11.5m across all, 0.179–0.186. P(success) = 100% for every one (stratified topline HR will be higher of course, but in the 0.31-.50 range, 99.99% chances) 
 
The only reason model choice does matter is for long term predictions.  But they all agree on what happens within the trial&#39;s observation window, which is all the HR needs.  
 
Fortunes will be made with sizeable positions.

Chris

Jeff Freedman

AstaAzaria

Easy E

Roger Rabbit $5,56

Matthew Olz

Adrian Morley

Christy Morgan

_level_m_

Steve

Killing It

Tony M

David Maibaum

Guy Chandler

Jeremy Dworkin

TucksMom

Lion

Mario

Caffeine Cowboy

Lester.

TTP222

DaddysHome1007

Remy van der Hulst

John

Artjom

StockTwits For Android 

Morten Skov Schiellerup

$SLS Thank you very much and congratulations for your dedication and expertise. &lt;3

StockTwits Web

EasyLode

StockTwits for iOS

Jesse101

thewatchmakerG48

$SLS 🎯🎯🎯 I said it around 2 weeks ago!!! The longer event 80 takes to achieve the more blockbuster this ticker is!!! 😎😎😎

Ferdinand Baudet

Stephen Rustom

$SLS it’s a lock folks. This is a money printing machine. Just hold

Sarah

$SLS This is why I full ported and am up over $400K since last year, it’s free money 😆

 Just a reminder that there are 99.99% chances of success for REGAL.  Failure is a statistical impossibility. 
 
For context, before the mixed-cure model, I built several different models.  I've attached the convergence and divergence between 6 models, that all lead to the same/similar result during the trial duration.  
 
Pure Cure: S(t) = p + (1-p)·exp(-λt) 67.9% cured forever  
Leaky Cure: "cured" patients relapse at 1-10% per year  
Weibull: S(t) = exp(-(t/η)^β) decelerating hazard, no plateau  
Log-Normal: heavy right tail, no true cure  
Piecewise Exponential: fast early decline, slow late decline  
 
The straight HR when BAT = 11.5m across all, 0.179–0.186. P(success) = 100% for every one (stratified topline HR will be higher of course, but in the 0.31-.50 range, 99.99% chances) 
 
The only reason model choice does matter is for long term predictions.  But they all agree on what happens within the trial's observation window, which is all the HR needs.  
 
Fortunes will be made with sizeable positions.

@yG19  I love the analysis and have been running some of my own. Do you have any recently published evidence that gives a strong insight into the BAT’s median OS so that I can get better statistical certainty for the parameters I am setting for BAT OS rates that are driven by stronger real world data. Happy to DM if it’s preferred

Kat Tastrophe

NuoriHarrastelija

  I love the analysis and have been running some of my own. Do you have any recently published evidence that gives a strong insight into the BAT’s median OS so that I can get better statistical certainty for the parameters I am setting for BAT OS rates that are driven by stronger real world data. Happy to DM if it’s preferred

Brett Thomas

@yG19 I’m all in!
I went from 7000 to 80,000 shares in 2 weeks.  Now I can sleep well knowing every passing day without an 80th event, drops that HR number even more making the BO war even more extreme!!!

I_Buy_Stock

Louis

C. H.

Captain

Dangerous12

Makoh

Shin

Pete

Rick Lee Taker

Wuzzyup

Crassius Curio

peacewealth7447

Si V

Brandon Skelton

Dave

Pieter Dee

Paul André Bekker

Bernd Roessle

Anthony

mrittika1971

 I’m all in!
I went from 7000 to 80,000 shares in 2 weeks.  Now I can sleep well knowing every passing day without an 80th event, drops that HR number even more making the BO war even more extreme!!!

Ricko4

@Bladetrader4965 Thank you, and certainly, if you look at the October 29th R&amp;D call, Dr. Jamy goes over this in detail.  In the Part 2 of the DD I shared, I have 7 sources as well for AML CR2 (not eligible for transplant) 
 
The biological cap from study after study is 6 to 10 (assume 6 to 12), or 8 to 10 (up to 12) 
 
In the Part 1 and Part 2 DD I shared, the machine learning models tested all the way up to 23 for BAT mOS. 
 
BAT mOS would have to be above 18 for the trial to fail, which is impossible. 
 
https://www.reddit.com/r/TheRaceTo10Million/comments/1repf0k/sls_part_2_and_final_deepest_due_diligence_for/

Philip

alec

Willie

Raymond Babbitt

reddit

$SLS Part 2 and FINAL (Deepest Due Diligence for REGAL Trial) (From a Deep Value Investor) (Predicting BAT mOS from Predictive Model)

 Thank you, and certainly, if you look at the October 29th R&D call, Dr. Jamy goes over this in detail.  In the Part 2 of the DD I shared, I have 7 sources as well for AML CR2 (not eligible for transplant) 
 
The biological cap from study after study is 6 to 10 (assume 6 to 12), or 8 to 10 (up to 12) 
 
In the Part 1 and Part 2 DD I shared, the machine learning models tested all the way up to 23 for BAT mOS. 
 
BAT mOS would have to be above 18 for the trial to fail, which is impossible. 
 


Keith Thompson

Nobody

Michał Tak

CMSP

6,700% ROI this quarter

GreyLock

Benjamin

@yG19 please send this to Dr. Fleming.. Great stuff.

Sood

Abel Grace

Herda Christian

Howard

 please send this to Dr. Fleming.. Great stuff.

Jerry aya

FakeEmpire51

Noah Herring

Peter Chester

@yG19 i just saw this stock trending and your graph, hence my question about REGAL.

 i just saw this stock trending and your graph, hence my question about REGAL.

@YosemiteSam7 REGAL is the Phase 3 Trial for GPS, in AML CR2 (not eligible for transplant).  It is extending lives by 3x to 4x, along with creating a cure fraction/extremely long survival tail/&quot;cure&quot; 
 
On reddit, I posted a Part 1 and Part 2 DD (due diligence).  If you google it, you should come across it.  Read through that and the comments/Q&amp;A and it will be very helpful and insightful. 
 
Upside from $5 a share is 5.5X to 32X

Alan

a. bol

awesome sauce

 REGAL is the Phase 3 Trial for GPS, in AML CR2 (not eligible for transplant).  It is extending lives by 3x to 4x, along with creating a cure fraction/extremely long survival tail/"cure" 
 
On reddit, I posted a Part 1 and Part 2 DD (due diligence).  If you google it, you should come across it.  Read through that and the comments/Q&A and it will be very helpful and insightful. 
 
Upside from $5 a share is 5.5X to 32X

Callen

@yG19 wow, any of these models far outpaces the 21 month mOS seen in p2. Is this due to unlimited GPS dosing and healthier trial population compared to p2? Or do you have other explanations?

 wow, any of these models far outpaces the 21 month mOS seen in p2. Is this due to unlimited GPS dosing and healthier trial population compared to p2? Or do you have other explanations?

@Bazzil Thank you, it&#39;s certainly due to the unlimited dosing and continuous dosing (Phase 2 was just 6 doses, with up to 12 max).  Included a section on this is in the Part 1 DD on reddit as well

 Thank you, it's certainly due to the unlimited dosing and continuous dosing (Phase 2 was just 6 doses, with up to 12 max).  Included a section on this is in the Part 1 DD on reddit as well

@yG19 thank you for the explanation and insight. much appreciated.

 thank you for the explanation and insight. much appreciated.

@yG19 what’s a sizeable position in your opinion? Thanks for the analysis 🙌🏼

 what’s a sizeable position in your opinion? Thanks for the analysis 🙌🏼

@Mkeol Glad the due diligence is helpful and insightful.  And I usually don&#39;t intervene in position sizing, as that is up to the person, but I believe anyone working with a small amount of relevant capital, should have a heavy sizeable concentrated position here. I have a very large position, and if it were not for my deep value wins from last year that I can&#39;t exit from due to short term capital gains, I would be all in. 
 
The 5.5X to 32X upside from $5 is real, and not an exaggeration at all, this will occur upon REGAL final analysis and buyout.

CannonPC

 Glad the due diligence is helpful and insightful.  And I usually don't intervene in position sizing, as that is up to the person, but I believe anyone working with a small amount of relevant capital, should have a heavy sizeable concentrated position here. I have a very large position, and if it were not for my deep value wins from last year that I can't exit from due to short term capital gains, I would be all in. 
 
The 5.5X to 32X upside from $5 is real, and not an exaggeration at all, this will occur upon REGAL final analysis and buyout.

@yG19 I have a position with a nice average price. - it’s not a small pair ion but maybe not ”sizeable” - that’s why I wanted to gauge what you thought is an amount that makes sense to you (procures that is reference dependant)

 I have a position with a nice average price. - it’s not a small pair ion but maybe not ”sizeable” - that’s why I wanted to gauge what you thought is an amount that makes sense to you (procures that is reference dependant)

@Mkeol Awesome, and again, it is person dependent, money is relative to each individual/institution and their own capacity. 
 
As mentioned, if it weren&#39;t were my deep value wins from last year that I can&#39;t yet exit due to short term capital gains, I would be all-in. 
 
It&#39;s the only stock I&#39;ve been adding to and I&#39;m just at a little over 806K shares (still adding every week).   
 
If you had to decide on a specific position amount, the people that have 10K to 50K+ shares or around that range is who I&#39;m most excited for. That will be hundreds of thousands to low millions upon buyout (simply the math of 5.5X to 32X upside from $5 a share, adjust accordingly for the current share price). That amount is life-changing as a base in life for people and their families.

 Awesome, and again, it is person dependent, money is relative to each individual/institution and their own capacity. 
 
As mentioned, if it weren't were my deep value wins from last year that I can't yet exit due to short term capital gains, I would be all-in. 
 
It's the only stock I've been adding to and I'm just at a little over 806K shares (still adding every week).   
 
If you had to decide on a specific position amount, the people that have 10K to 50K+ shares or around that range is who I'm most excited for. That will be hundreds of thousands to low millions upon buyout (simply the math of 5.5X to 32X upside from $5 a share, adjust accordingly for the current share price). That amount is life-changing as a base in life for people and their families.

@yG19 I’m at 8000, and will consider maybe more.. hopefully I get to 10

 I’m at 8000, and will consider maybe more.. hopefully I get to 10